Intco Medical Technology's (SZSE:300677) Five-year Total Shareholder Returns Outpace the Underlying Earnings Growth
Intco Medical Technology's (SZSE:300677) Five-year Total Shareholder Returns Outpace the Underlying Earnings Growth
For many, the main point of investing in the stock market is to achieve spectacular returns. And we've seen some truly amazing gains over the years. Don't believe it? Then look at the Intco Medical Technology Co., Ltd. (SZSE:300677) share price. It's 363% higher than it was five years ago. This just goes to show the value creation that some businesses can achieve. Unfortunately, though, the stock has dropped 6.9% over a week. However, this might be related to the overall market decline of 2.8% in a week.
对许多人来说,投资股市的主要目的是获得丰厚的回报。而这些年来,我们确实看到了令人惊叹的收益。 不相信吗?那就看看英科医疗科技有限公司(SZSE:300677)的股价。它比五年前上涨了363%。这正好说明了一些企业能够创造的价值。 不幸的是,这只股票在一周内下跌了6.9%。然而,这可能与整体市场在一周内下跌了2.8%有关。
While this past week has detracted from the company's five-year return, let's look at the recent trends of the underlying business and see if the gains have been in alignment.
虽然过去的一周削弱了公司的五年回报,但让我们看看业务的最近趋势,并查看收益是否已对齐。
To paraphrase Benjamin Graham: Over the short term the market is a voting machine, but over the long term it's a weighing machine. By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time.
引用本杰明·格雷厄姆的话:在短期内,市场是投票机,但在长期内,市场是称重机。通过比较每股收益(EPS)和股票价格的时间变化,我们可以感受到投资者对公司的态度随时间而变化。
During five years of share price growth, Intco Medical Technology achieved compound earnings per share (EPS) growth of 28% per year. This EPS growth is slower than the share price growth of 36% per year, over the same period. This suggests that market participants hold the company in higher regard, these days. That's not necessarily surprising considering the five-year track record of earnings growth.
在五年的股价增长中,英科医疗的每股收益(EPS)实现了每年28%的复合增长。这一EPS增长速度慢于同期股价36%的增长。这表明市场参与者对该公司的评价在逐渐提高。考虑到五年的盈利增长记录,这并不令人惊讶。
The company's earnings per share (over time) is depicted in the image below (click to see the exact numbers).
该公司的每股收益(随时间的推移)如下图所示(单击可查看确切数字)。
We know that Intco Medical Technology has improved its bottom line lately, but is it going to grow revenue? If you're interested, you could check this free report showing consensus revenue forecasts.
我们知道英科医疗最近改善了其底线,但它会增长营业收入吗?如果你感兴趣,可以查看这份免费的报告,显示一致的营业收入预测。
What About Dividends?
关于分红派息的问题
When looking at investment returns, it is important to consider the difference between total shareholder return (TSR) and share price return. The TSR is a return calculation that accounts for the value of cash dividends (assuming that any dividend received was reinvested) and the calculated value of any discounted capital raisings and spin-offs. Arguably, the TSR gives a more comprehensive picture of the return generated by a stock. We note that for Intco Medical Technology the TSR over the last 5 years was 391%, which is better than the share price return mentioned above. This is largely a result of its dividend payments!
在考虑投资回报时,重要的是要考虑总股东回报(TSR)和股价回报之间的差异。TSR是一个回报计算,考虑到现金分红的价值(假设收到的任何分红都被再投资)以及任何折扣融资和剥离的计算价值。可以说,TSR提供了一个更全面的股票所产生的回报的视角。我们注意到,英科医疗在过去5年的TSR为391%,这比上述的股价回报更好。这在很大程度上是由于其分红支付!
A Different Perspective
另一种看法
It's good to see that Intco Medical Technology has rewarded shareholders with a total shareholder return of 28% in the last twelve months. And that does include the dividend. Having said that, the five-year TSR of 37% a year, is even better. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Consider risks, for instance. Every company has them, and we've spotted 2 warning signs for Intco Medical Technology you should know about.
很高兴看到英科医疗在过去12个月中以28%的总股东回报奖励了股东。并且这包括了分红。话虽如此,五年每年37%的TSR甚至更好。我发现从长期来看股价作为业务表现的代 proxy 是非常有趣的。但要真正获得深入见解,我们还需要考虑其他信息。例如,考虑风险。每个公司都有风险,我们已经发现了英科医疗你应该知道的2个警告信号。
If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of companies that have proven they can grow earnings.
如果您愿意查看另一家公司(具有潜在的更好财务状况),请不要错过这个免费的公司列表,证明它们可以增长收益。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.
请注意,本文中引用的市场回报反映了目前在中国交易所上市的股票的市场加权平均回报。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?对内容感到担忧吗?请直接与我们联系。或者,发送电子邮件至editorial-team @ simplywallst.com。
Simply Wall St的这篇文章是一般性质的。我们仅基于历史数据和分析师预测提供评论,使用公正的方法,我们的文章并非意在提供财务建议。这并不构成买入或卖出任何股票的建议,并且不考虑您的目标或财务状况。我们旨在为您带来基于基础数据驱动的长期聚焦分析。请注意,我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St对提及的任何股票都没有持仓。